Charles River Laboratories

CRL

Market cap $8.7B

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the Company will participate in the Noble Capital Markets Virtual Equity Conference on June 3 and 4, 2026. CRA Chairman and Chief Executive Officer Paul Maleh is scheduled to present at 11:00 a.m. EDT on Wednesday, June 3. A live webcast will be available on the Company's investor relations website. An archived replay wil.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River's expertise in biologics and cell therapy GMP testing to support MEDIPOST's global cell therapy pipeline, starting i.

Evaluate Charles River's (CRL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timelines, and enhances pathologist efficiency, and supports the reduction of animal use in nonclinical research where scientifically appropriate. By fully integrating digital pathology across the histology and pathology workflow, Charles River is com.

Charles River Laboratories International NYSE: CRL reported first-quarter 2026 results that management said were in line to slightly ahead of its prior outlook, while reaffirming its full-year organic revenue and non-GAAP earnings guidance and outlining a refreshed strategic framework under new Chief Executive Officer Birgit Girshick.

Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?

Charles River Laboratories International, Inc. (NYSE:CRL) posted upbeat earnings for the first quarter, but lowered its FY2026 forecast on Thursday.

Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript

Charles River Laboratories is downgraded to 'Sell' as shares have rallied 57% in the past year, outpacing fundamentals. Despite Q1 stabilization, organic revenue declined 1.5% and margins compressed, with near-term growth muted and longer-term AI and regulatory risks looming. CRL maintains 2026 EPS guidance of $10.80–$11.30 but trades at 17.5x forward earnings—still at a discount to its history but not considered cheap.